Armata Pharmaceuticals, Inc. (ARMP) P/E Ratio History
Historical price-to-earnings valuation from 2013 to 2015
Loading P/E history...
ARMP Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Armata Pharmaceuticals, Inc. (ARMP) trades at a price-to-earnings ratio of -17.5x, with a stock price of $9.15 and trailing twelve-month earnings per share of $-1.29.
The current P/E is 274% below its 5-year average of 10.1x. Over the past five years, ARMP's P/E has ranged from a low of 1.4x to a high of 48.3x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, ARMP trades at a 178% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, ARMP trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ARMP DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ARMP P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $339M | 14.3 | - | -60% | |
| $2B | 14.1 | - | -26% | |
| $10B | 13.1Lowest | 1.87Best | +29%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
ARMP Historical P/E Data (2013–2015)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2015 Q2 | $1309.00 | $27.11 | 48.3x | +380% | |
| FY2015 Q1 | $2065.00 | $273.51 | 7.5x | -25% | |
| FY2014 Q4 | Wed Dec 31 2014 00:00:00 GM | $1435.00 | $342.11 | 4.2x | -58% |
| FY2014 Q3 | $1512.00 | $793.20 | 1.9x | -81% | |
| FY2014 Q2 | Mon Jun 30 2014 00:00:00 GM | $3066.00 | $541.20 | 5.7x | -44% |
| FY2014 Q1 | Mon Mar 31 2014 00:00:00 GM | $4046.00 | $2768.58 | 1.5x | -85% |
| FY2013 Q4 | $3500.00 | $2576.36 | 1.4x | -86% |
Average P/E for displayed period: 10.1x
See ARMP's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ARMP Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ARMP vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonARMP — Frequently Asked Questions
Quick answers to the most common questions about buying ARMP stock.
Is ARMP stock overvalued or undervalued?
ARMP trades at -17.5x P/E, below its 5-year average of 10.1x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does ARMP's valuation compare to peers?
Armata Pharmaceuticals, Inc. P/E of -17.5x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is ARMP's PEG ratio?
ARMP PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2013-2015.